Fat Burning Pharmaceutical Raw Materials Rimonabant / Acomplia CAS 168273-06-1

  Pharmaceutical Raw Materials Rimonabant / Acomplia CAS 168273-06-1 For Fat Burning

Abstract

Rimonabant is a weight loss drug, can significantly reduce weight, reduce waist circumference and reduce risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the presence of clinical obesity or heart disease people at risk.

Rimonabant as a new weight loss drug, can also be used to quit smoking. Not only lose weight, but also lower blood pressure, cholesterol and blood sugar, clinical study found that subjects taking one to two months later, the weight can be reduced on average six to eight kilograms.

An experimental wonder drug, Rimonabant, helps you lose weight, quit smoking and it also helps protect your heart. Trials have shown that 33% of people on Rimonabant lost 10% of body weight and kept their weight down for two years - this is a record, no other diet drug has managed to keep a person's weight down for so long. The second 33% lost 5% of body weight and kept it down. As well as keeping you lean, the drug also helps you quit the smoking habit. This will be of great interest for many smokers who are afraid to give up because they say they will put on loads of weight if they do.

COA

Function 

Rimonabant / Acomplia is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil.

Rimonabant / Acomplia,Developed by Sanofi-Aventis, Acomplia (Rimonabant) is a selective CB1 receptor antagonist. In other words, Rimonabant is intended to promote weight loss by reducing the total number of calories an individual consumes on a daily basis.

Rimonabant / Acomplia works by blocking endogenous from binding to neuronal CB1 receptors. The activation of these receptors by endogenous , such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.

How does rimonabant work?

Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle2.

Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis.
CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system).3,4 The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.

Dosage

It is expected that the usual dose of rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.

Although rimonabant can be used in patients with mild hepatic impairment, caution is advised in patients with moderate impairment. This medication is not recommended for those with severe hepatic impairment.

Rimonabant may be used cautiously in patients with mild-to-moderate renal impairment, but it is not recommended for patients who are severely renally impaired.

Weight Loss Powders series